Cyclophosphamide in Mobilizing Stem Cells in Patients with Non-Hodgkin’s Lymphoma or Multiple Myeloma Undergoing Transplant

Inclusion Criteria

• All patients must have a pathologic diagnosis of one of the following malignancies: * Non-Hodgkin’s lymphoma, including B- and T-cell lymphoma * Multiple myeloma or another plasma cell dyscrasia (Waldenstrom, Amyloidosis)
• The patient must be approved for transplant by the treating Transplant physician; this includes completion of their pre-transplant workup, as directed by standard DHMC SOPs
• This must be the patient’s FIRST mobilization attempt
• Patients are eligible if an autologous transplant is planned within approximately 12 months from the time of collection of cells
• Prior treatment: no previous cytotoxic chemotherapy within 4 weeks prior to initiation of therapy; (this does not include immunomodulatory drugs [IMIDs], proteasome inhibitors, monoclonal antibodies or steroids)
• No radiation within 4 weeks of mobilization attempt
• No significant co-morbid medical or psychiatric illness that would significantly compromise the patient’s clinical care and chances of survival
• Informed consent must be signed prior to the treatment; patients must willingly consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side effects, risks and discomforts; (human protection committee approval of this protocol and a consent form is required)

Exclusion Criteria

• Medical, social, or psychological factors that would prevent the patient from receiving or cooperating with the full course of therapy
• Documented hypersensitivity to any of the drugs used in the protocol